Chitosan-coated superparamagnetic iron oxide nanoparticles for doxorubicin delivery: Synthesis and anticancer effect against human ovarian cancer cells

Chemical Biology and Drug Design

Volumn 82, Issue 3, 2013, Pages 296-306

  Javid, Amaneh ^a   Ahmadian, Shahin ^a   Saboury, Ali A ^a   Kalantar, Seyed M ^b   Rezaei Zarchi, Saeed ^c  

^a UNIVERSITY OF TEHRAN   (Iran)

^b SHAHID SADOUGHI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c PAYAME NOOR UNIVERSITY   (Iran)

Author keywords

Chitosan; Doxorubicin; Drug loading; Encapsulation; Human ovarian cancer; Iron oxide

Indexed keywords

CHITOSAN; DOXORUBICIN; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CROSS LINKING; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG SYNTHESIS; DRUG UPTAKE; EMULSION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IC 50; IMMUNOBLOTTING; IRON TRANSPORT; NANOENCAPSULATION; OVARY CANCER; PARTICLE SIZE; PRIORITY JOURNAL;

CHITOSAN; DOXORUBICIN; DRUG LOADING; ENCAPSULATION; HUMAN OVARIAN CANCER; IRON OXIDE;

ANTIBIOTICS, ANTINEOPLASTIC; BCL-2-ASSOCIATED X PROTEIN; CELL LINE, TUMOR; CELL SURVIVAL; CHITOSAN; DOXORUBICIN; DRUG CARRIERS; FEMALE; FERRIC COMPOUNDS; HUMANS; HYDROGEN-ION CONCENTRATION; INHIBITOR OF APOPTOSIS PROTEINS; MAGNETITE NANOPARTICLES; NF-KAPPA B; OVARIAN NEOPLASMS; PARTICLE SIZE; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 84882869984     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/cbdd.12145     Document Type: Article

References (36)

1. Ferrari M. (2005) Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer;5:161-171.
2. Chertok B., Moffat B.A., David A.E., Yu F., Bergemann C., Ross B.D. (2008) Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors. Biomaterials;29:487-496.
3. Kikumori T., Kobayashi T., Sawaki M., Imai T. (2009) Anti-cancer effect of hyperthermia on breast cancer by magnetite nanoparticle-loaded anti-HER2 immunoliposomes. Breast Cancer Res Treat;113:435-441.
4. Marchal F., Pic E., Pons T., Dubertret B., Bolotine L., Guillemin F. (2008) Quantum dots in oncological surgery: the future for surgical margin status? Bull Cancer;95:1149-1153.
5. Kim E.H., Lee H.S., Kwak B.K., Kim B.K. (2005) Synthesis of ferrofluid with magnetic nanoparticles by sonochemical method for MRI contrast agent. J Magn Magn Mater;289:328-330.
6. 4 nanoparticles as contrast agents for magnetic resonance imaging. J Korean Soc Magn Reson Med;4:27-32.
7. 4 thermo-responsive and magnetic composite micelles. Mater Lett;62:4425-4427.
8. Chandra S., Mehta S., Nigam S., Bahadur D. (2010) Dendritic magnetite nanocarriers for drug delivery applications. New J Chem;34:648-655.
9. 2 gas. Physica E;42:1824-1829.
10. Sahoo Y., Pizem H., Fried T., Golodnitsky D., Burstein L., Sukenik S.N., Markovich G. (2001) Alkyl phosphonate/phosphate coating on magnetite nanoparticles: a comparison with fatty acids. Langmuir;17:7907-7911.
11. Nayak S., Lee S., Chmielewski J., Lyon L.A. (2004) Folate-mediated cell targeting and cytotoxicity using thermoresponsive microgels. J Am Chem Soc;126:10258-10259.
12. Mammen M., Choi S.K., Whitesides G.M. (1998) Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors. Angew Chem Int Ed;37:2754-2794.
13. Fonseca C., Simões S., Gaspar R. (2002) Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. J Control Release;83:273-286.
14. Müller B., Kreuter J. (1999) Enhanced transport of nanoparticle associated drugs through natural and artificial membranes - a general phenomenon? Int J Pharm;178:23-32.
15. Xu Y., Du Y. (2003) Effect of molecular structure of chitosan on protein delivery properties of chitosan nanoparticles. Int J Pharm;250:215-226.
16. Qi L.F., Xu Z.R., Jiang X. (2004) Preparation and antibacterial activity of chitosan nanoparticles. Carbohydr Res;339:2693-2700.
17. Artursson P., Lindmark T., Davis S.S., Illum L. (2004) Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm Res;11:1358-1361.
18. Fernández-Urrusuno R., Calvo P., Remuñán-López C., Vila-Jato J.L., Alonso M.J. (1999) Enhancement of nasal absorption of insulin using chitosan nanoparticles. Pharm Res;16:1576-1581.
19. Vårum K.M., Myhr M.M., Hjerde R.J., Smidsrød O. (1997) In vitro degradation rates of partially N-acetylated chitosans in human serum. Carbohydr Res;299:99-101.
20. Miao Y., Tan S.N. (2000) Amperometric hydrogen peroxide biosensor based on immobilization of peroxidase in chitosan matrix crosslinked with glutaraldehyde. Analyst;125:1591-1594.
21. 2 contrast agent for magnetic resonance imaging. J Korean Phys Soc;56:868-873.
22. 4 nanoparticles for controlled delivery of methotrexate. Res Pharm Sci;8:25-33.
23. Jain T.K., Morales M.A., Sahoo S.K., Leslie-Pelecky D.L., Labhasetwar V. (2005) Iron oxide nanoparticles for sustained delivery of anticancer agents. Mol Pharm;2:194-205.
24. Gupta A.K., Gupta M. (2005) Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials;26:3995-4021.
25. Saifuddin N., Dinara S. (2012) Immobilization of Saccharomyces cerevisiae onto cross-linked chitosan coated with magnetic nanoparticles for adsorption of Uranium (VI) ions. Adv Nat Appl Sci;6:249-267.
26. Schwertmann U., Cornell R.M. (2007) Iron Oxides in the Laboratory: Preparation and Characterization, 2nd edn. Germany: Wiley-VCH Verlag GmbH; p. 5-18.
27. Hong S., Lim W.T., Rhee I. (2006) Relaxation rate of hydrogen protons of water molecules in an aqueous solution of dextran coated ferrite nanoparticles. J Korean Phys Soc;49:676-681.
28. Chen Y., Mohanraj V.J., Parkin J.E. (2003) Chitosan-dextran sulfate nanoparticles for delivery of an antiangiogenesis peptide. Lett Pept Sci;10:621-627.
29. Vila A., Sanchez A., Tobio M., Calvo P., Alonso M.J. (2002) Design of biodegradable particles for protein delivery. J Control Release;78:15-24.
30. Redhead H.M., Davis S.S., Illum L. (2001) Drug delivery in poly(lactide-co-glycolide) nanoparticles surface modified with poloxamer 407 and poloxamine 908: in vitro characterization and in vivo evaluation. J Control Release;70:353-363.
31. Wang T.T., Wei J., Qian X.P., Ding Y.T., Yu L.X., Liu B.R. (2008) Gambogic acid, a potent inhibitor of survivin, reverses docetaxel resistance in gastric cancer cells. Cancer Lett;262:214-222.
32. Wang L., Zhang G.M., Feng Z.H. (2003) Down-regulation of survivin expression reversed multidrug resistance in adriamycin- resistant HL-60/ADR cell line. Acta Pharmacol Sin;24:1235-1240.
33. Ling X., Bernacki R.J., Brattain M.G., Li F.Z. (2004) Induction of survivin expression by taxol (paclitaxel) is an early event, which is independent of taxol mediated G2/M arrest. J Biol Chem;279:15196-15203.
34. Adams J.M., Cory S. (1998) The Bcl-2 protein family: arbiters of cell survival. Science;281:1322-1326.
35. Kirkin V., Joos S., Zornig M. (2004) The role of Bcl-2 family members in tumorigenesis. Biochim Biophys Acta;1644:229-249.
36. Pandey M.K., Sung B., Ahn K.S. (2007) Gambogic acid, a novel ligand for transferrin receptor, potentiates TNF-induced apoptosis through modulation of the nuclear factor-κB signaling pathway. Blood;110:3517-3525.